File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection

TitleAntibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection
Authors
Issue Date1996
Citation
New England Journal of Medicine, 1996, v. 334, n. 20, p. 1292-1297 How to Cite?
AbstractBackground. The recent identification in patients with Kaposi's sarcoma of DNA sequences with homology to gammaherpesviruses has led to the hypothesis that a newly identified virus, Kaposi's sarcoma-associated herpeslike virus (KSHV), has a role in the pathogenesis of Kaposi's sarcoma. We developed serologic markers for KSHV infection. Methods. KSHV antigens were prepared from a cell line (BC-1) that contains the genomes of both KSHV and the Epstein-Barr virus (EBV). We used immunoblot and immunofluorescence assays to examine serum samples from 102 patients with human immunodeficiency virus type 1 (HIV-1) infection for antibodies to KSHV-associated proteins and to distinguish these antibodies from antibodies to EBV antigens. A positive serologic response was defined by the recognition of an antigenic polypeptide, p40, in n-butyrate-treated BC-1 cells and by the absence of p40 recognition in untreated BC-1 cells or EBV-infected, KSHV-negative cells. The detection by the immunofluorescence assay of 10 to 20 times more antigen- positive cells in n-butyrate-treated BC-1 cells than in untreated cells was considered a positive response. Results. Antibodies to the p40 antigen expressed by chemically treated BC-1 cells were identified in 32 of 48 HIV- 1-infected patients with Kaposi's sarcoma (67 percent), as compared with only 7 of 54 HIV-1-infected patients without Kaposi's sarcoma (13 percent). These results were confirmed by an immunofluorescence assay. The positive predictive value of the serologic tests for Kaposi's sarcoma was 82 percent, and the negative predictive value 75 percent. Conclusions. The presence of antibodies to a KSHV antigenic peptide correlates with the presence of Kaposi's sarcoma in a high-risk population and provides further evidence of an etiologic role for KSHV.
Persistent Identifierhttp://hdl.handle.net/10722/285588
ISSN
2019 Impact Factor: 74.699
2015 SCImago Journal Rankings: 14.619

 

DC FieldValueLanguage
dc.contributor.authorMiller, George-
dc.contributor.authorRigsby, Michael O.-
dc.contributor.authorHeston, Lee-
dc.contributor.authorGrogan, Elizabeth-
dc.contributor.authorSun, Ren-
dc.contributor.authorMetroka, Craig-
dc.contributor.authorLevy, Jay A.-
dc.contributor.authorGao, Shou Jiang-
dc.contributor.authorChang, Yuan-
dc.contributor.authorMoore, Patrick-
dc.date.accessioned2020-08-18T04:56:08Z-
dc.date.available2020-08-18T04:56:08Z-
dc.date.issued1996-
dc.identifier.citationNew England Journal of Medicine, 1996, v. 334, n. 20, p. 1292-1297-
dc.identifier.issn0028-4793-
dc.identifier.urihttp://hdl.handle.net/10722/285588-
dc.description.abstractBackground. The recent identification in patients with Kaposi's sarcoma of DNA sequences with homology to gammaherpesviruses has led to the hypothesis that a newly identified virus, Kaposi's sarcoma-associated herpeslike virus (KSHV), has a role in the pathogenesis of Kaposi's sarcoma. We developed serologic markers for KSHV infection. Methods. KSHV antigens were prepared from a cell line (BC-1) that contains the genomes of both KSHV and the Epstein-Barr virus (EBV). We used immunoblot and immunofluorescence assays to examine serum samples from 102 patients with human immunodeficiency virus type 1 (HIV-1) infection for antibodies to KSHV-associated proteins and to distinguish these antibodies from antibodies to EBV antigens. A positive serologic response was defined by the recognition of an antigenic polypeptide, p40, in n-butyrate-treated BC-1 cells and by the absence of p40 recognition in untreated BC-1 cells or EBV-infected, KSHV-negative cells. The detection by the immunofluorescence assay of 10 to 20 times more antigen- positive cells in n-butyrate-treated BC-1 cells than in untreated cells was considered a positive response. Results. Antibodies to the p40 antigen expressed by chemically treated BC-1 cells were identified in 32 of 48 HIV- 1-infected patients with Kaposi's sarcoma (67 percent), as compared with only 7 of 54 HIV-1-infected patients without Kaposi's sarcoma (13 percent). These results were confirmed by an immunofluorescence assay. The positive predictive value of the serologic tests for Kaposi's sarcoma was 82 percent, and the negative predictive value 75 percent. Conclusions. The presence of antibodies to a KSHV antigenic peptide correlates with the presence of Kaposi's sarcoma in a high-risk population and provides further evidence of an etiologic role for KSHV.-
dc.languageeng-
dc.relation.ispartofNew England Journal of Medicine-
dc.titleAntibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1056/NEJM199605163342003-
dc.identifier.pmid8609946-
dc.identifier.scopuseid_2-s2.0-15844378212-
dc.identifier.volume334-
dc.identifier.issue20-
dc.identifier.spage1292-
dc.identifier.epage1297-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats